hormoneNot FDA-approvedResearch chemicalNever studied in humans; only in silico toxicology and equine/anti-doping metabolite work existSold online as a research chemical, not an approved drugProhibited in sport by WADA as a SARM
ACP-105Benefits, Dosage & Interactions
ACP-105 is a selective androgen receptor modulator (SARM) that has been investigated for its potential to stimulate anabolic activity in specific tissues, such as muscle and bone, while theoretically minimizing androgenic side effects in other tissues, like the prostate or sebaceous glands.
Researched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
Not established
Default unit
mg
References & evidence
Documents the ACP-105 entry is written from. Each number matches an inline marker above.
- [1]First multifaceted ADME profile of ACP-105 (CAS: 1048998-11-3): a novel non-steroidal selective androgen receptor modulator used as doping in sports-integrative in silico toxicological studies for clinical and forensic toxicology purposesFijałkowska O, Jurowski K · Archives of Toxicology · 2025 · Peer-reviewed · PMID 40928534
- [2]Investigation of Equine In Vivo and In Vitro Derived Metabolites of the Selective Androgen Receptor Modulator (SARM) ACP-105 for Improved Doping ControlBroberg MN, Knych H, Bondesson U, et al. · Metabolites · 2021 · Peer-reviewed · PMID 33535528
References & Evidence
Sources on this page that document ACP-105 dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is ACP-105 studied for?
What is ACP-105?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
ACP-105 is a selective androgen receptor modulator (SARM) that has been investigated for its potential to stimulate anabolic activity in specific tissues, such as muscle and bone, while theoretically minimizing androgenic side effects in other tissues, like the prostate or sebaceous glands. Developed in the early 2000s, it functions by selectively binding to androgen receptors. Preclinical research has explored its therapeutic potential in conditions associated with muscle wasting and bone demineralization. As a research chemical, its use in humans is not approved by regulatory bodies like the FDA for any medical indication. Therefore, information regarding its efficacy and safety in humans is primarily derived from preclinical studies and anecdotal reports, which are not a substitute for rigorous clinical trials. The compound is understood to have a relatively high binding affinity to the androgen receptor, similar to some endogenous androgens, which is a key aspect of its proposed mechanism of action (PubChem).
What does the research say about ACP-105?
Tap a section to expand.
ACP-105 functions as a partial agonist at androgen receptors (ARs). Unlike traditional anabolic steroids, which tend to activate ARs systemically, SARMs like ACP-105 are designed to exhibit tissue-selective activity. This selectivity is thought to arise from differences in AR conformation when bound to the SARM, leading to varied recruitment of coactivator and corepressor proteins in different tissues. In tissues such as skeletal muscle and bone, ACP-105 is hypothesized to promote an anabolic response by enhancing protein synthesis and bone mineralization. Conversely, in tissues like the prostate, its partial agonist activity or altered receptor conformation is proposed to result in reduced androgenic effects compared to testosterone (Examine.com, PubChem). This tissue selectivity is the central premise behind the development of SARMs—to harness the therapeutic benefits of androgen receptor activation while mitigating undesirable side effects typically associated with non-selective AR agonists.
Source for this section: Sources for How does ACP-105 work?: Jumps to this entry in the sources and references list at the end of the page.
Preclinical studies have explored the potential benefits of ACP-105 primarily in areas related to muscle and bone health. Research in *in vitro* and *in vivo* models has indicated that ACP-105 may:
* **Support muscle mass:** Studies in animal models suggest that ACP-105 can increase lean body mass and muscle strength by promoting anabolism in skeletal muscle tissue (Examine.com).
* **Enhance bone mineral density:** Preclinical data suggests a positive effect on bone health, potentially increasing bone mineral density and strength, which could be relevant for conditions like osteoporosis (PubChem).
* **Improve physical function:** The anabolic effects on muscle and bone could theoretically translate into improvements in physical performance and functional capacity, though this has not been robustly demonstrated in human clinical trials.
It is important to emphasize that these potential benefits are derived from preclinical research and are not established for human use. The safety, efficacy, and optimal application of ACP-105 in humans remain undefined due to the lack of comprehensive clinical trials.
The evidence supporting the effects and safety of ACP-105 is primarily from preclinical investigations. Studies in animal models, particularly rodents, have demonstrated its ability to induce anabolic effects in muscle and bone. For example, research has shown improvements in lean muscle mass and bone mineral density in castrated male rats treated with ACP-105, without significantly enlarging the prostate gland at equipotent anabolic doses compared to testosterone (PubChem). These animal studies provide the foundational understanding of ACP-105's tissue-selective properties and its potential therapeutic avenues. However, there is a distinct lack of published clinical trials in humans. This means that data on human pharmacokinetics, pharmacodynamics, efficacy in specific conditions, and long-term safety is not available from randomized, controlled studies. Conclusions drawn from anecdotal reports or non-peer-reviewed sources should be approached with extreme caution, as they do not meet scientific standards for evidence. Regulatory bodies emphasize that compounds without approved clinical trials lack established safety and effectiveness for human use.
As a research chemical with limited human data, a comprehensive list of side effects for ACP-105 is not firmly established. Based on its mechanism as a SARM, potential side effects, often extrapolated from other SARMs and preclinical observations, *could* include:
* **Hormonal suppression:** Despite claims of tissue selectivity, SARMs can still cause suppression of endogenous testosterone production, which might lead to symptoms such as fatigue, mood changes, and decreased libido. The extent of suppression can vary.
* **Lipid profile alterations:** Some SARMs have been observed to negatively impact lipid profiles, leading to changes in HDL (good cholesterol) and LDL (bad cholesterol) levels.
* **Liver markers:** There have been anecdotal reports and some preclinical suggestions of potential liver enzyme elevation with SARM use, though direct evidence for ACP-105 is scarce.
* **Androgenic effects:** While designed to be selective, residual androgenic activity might still manifest in some individuals, potentially leading to mild acne, hair shedding, or slight voice changes.
* **Cardiovascular concerns:** The long-term cardiovascular impact of SARMs, including ACP-105, is unknown.
* **Vision changes:** There are anecdotal reports circulating about possible vision changes with some SARMs, though this effect has not been clinically substantiated for ACP-105.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
ACP-105 is an investigational compound not approved for human use by regulatory agencies like the FDA. Therefore:
* **Lack of human safety data:** There is a significant paucity of robust, peer-reviewed clinical data on the safety and long-term effects of ACP-105 in humans. All information is primarily derived from preclinical studies or anecdotal reports.
* **Potential for unlisted side effects:** Due to the limited research, there may be unknown or uncharacterized side effects that could arise with human exposure.
* **Product purity and concentration:** Because it is sold as a research chemical, the purity, concentration, and actual ingredients in commercially available ACP-105 products can be highly variable and may not match labeling, posing significant health risks (FDA label warnings).
* **Hormonal disruption:** Despite being a SARM, ACP-105 can still interfere with the body's natural hormone balance, potentially leading to adverse effects on the endocrine system.
* **Legal status:** The legal status of ACP-105 for personal use varies by region and can be subject to change. Use outside of a controlled research setting may carry legal implications.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Given that ACP-105 is an unapproved research chemical, specific contraindications based on clinical evidence are not established. However, based on its proposed mechanism of action and general understanding of hormone-modulating compounds, potential contraindications *could* include:
* **Pregnancy and breastfeeding:** Potential for hormonal disruption and unknown effects on fetal development or infant health.
* **Pre-existing hormonal conditions:** Individuals with prostate conditions, breast cancer, or other hormone-sensitive cancers should avoid such compounds due to potential for exacerbation or interference with treatment.
* **Liver or kidney disease:** As with most novel compounds, there is a theoretical risk of metabolic burden, especially without established safety profiles in these populations.
* **Cardiovascular disease:** Due to unknown long-term cardiovascular impacts.
* **Children and adolescents:** Hormonal modulators can significantly impact growth and development.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to the absence of human clinical trial data for ACP-105, specific drug-drug interactions are unknown. However, caution would strongly be advised when combining it with:
* **Other hormone-modulating compounds:** Mixing with other SARMs, anabolic steroids, or hormone replacement therapies could lead to unpredictable and potentially severe hormonal imbalances, exacerbating side effects or suppression.
* **Liver-toxic medications:** If ACP-105 carries a risk of hepatic strain, combining it with other compounds known to be hepatotoxic (e.g., certain antibiotics, antifungals, or over-the-counter pain relievers) could increase the risk of liver damage.
* **Blood thinners (anticoagulants):** Any compound affecting metabolic pathways could theoretically alter the efficacy or increase the bleeding risk associated with anticoagulants.
* **Medications affecting lipid profiles:** Combining with other agents that impact cholesterol levels could lead to exaggerated or detrimental changes to lipid health.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
ACP-105 has an estimated half-life of approximately 24 hours. Given this half-life, a single daily administration is often considered in preclinical models to maintain relatively stable blood concentrations. For human research purposes, if it were to be clinically investigated, this would typically involve once-daily dosing. When considering compounds like ACP-105, whether it is taken with or without food is generally not expected to significantly alter its absorption or efficacy, though specific pharmacokinetic data in humans is lacking (PubChem). Users in unofficial contexts may choose to consume it at any time of day, depending on personal preference or perceived convenience, without strong evidence to suggest one timing is superior to another. Individual needs vary — talk to a licensed clinician.
Source for this section: Sources for When should you take ACP-105?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about ACP-105 is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with ACP-105?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about ACP-105
ACP-105 is a hormone. The references summarized come from NIH and PubMed records, FDA labeling where it exists, and Mayo Clinic patient material.
ACP-105 is commonly discussed in the context of supporting muscle and bone-joint. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For ACP-105, it is typically taken null. Always follow the specific dose your clinician or the product label prescribes.
ACP-105 carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
As a hormone, ACP-105 can overlap with other supplements, prescription medicines, hormones and peptides. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers ACP-105 with no sign-up.
Whether ACP-105 fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to ACP-105. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for ACP-105 varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of ACP-105 depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For ACP-105 the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 11638442(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/11638442
Verify at
Publisher search links for ACP-105. These are places to check the information — they are not citations, so they are not numbered.
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on ACP-105?
Plain-text summary, safe to quote verbatim:
ACP-105 is a selective androgen receptor modulator (SARM) that has been investigated for its potential to stimulate anabolic activity in specific tissues, such as muscle and bone, while theoretically minimizing androgenic side effects in other tissues, like the prostate or sebaceous glands.
Source: DoseRoutine — https://doseroutine.com/library/acp-105
ACP-105 cheat sheet
DoseRoutine cheat sheet · Hormone
ACP-105
ACP-105 is a selective androgen receptor modulator (SARM) that has been investigated for its potential to stimulate anabolic activity in specific tissues, such as muscle and bone, while theoretically minimizing androgenic side effects in other tissues, like the prostate or sebaceous glands.
Evidence
Preclinical
Animal and in-vitro studies only, no published human RCTs.
Not FDA-approvedResearch chemicalNever studied in humans; only in silico toxicology and equine/anti-doping metabolite work existSold online as a research chemical, not an approved drugProhibited in sport by WADA as a SARMMuscleBone Joint
Key references
- First multifaceted ADME profile of ACP-105 (CAS: 1048998-11-3): a novel non-steroidal selective androgen receptor modulator used as doping in sports-integrative in silico toxicological studies for clinical and forensic toxicology purposes (2025)
- Investigation of Equine In Vivo and In Vitro Derived Metabolites of the Selective Androgen Receptor Modulator (SARM) ACP-105 for Improved Doping Control (2021)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/acp-105
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). ACP-105 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/acp-105
What compounds are similar to ACP-105?
Others in the hormone category or studied for the same goals.
Which goals is ACP-105 used for?
Other compounds studied for the same benefits as ACP-105.
Muscle & Strength
See all →Continue exploring
See every compound DoseRoutine catalogs for these goals.